150 related articles for article (PubMed ID: 19625102)
1. Delivering cytokines at tumor site: The immunocytokine-conjugated anti-EDB-fibronectin antibody case.
Ronca R; Sozzani S; Presta M; Alessi P
Immunobiology; 2009; 214(9-10):800-10. PubMed ID: 19625102
[TBL] [Abstract][Full Text] [Related]
2. Immunocytokines: a novel class of potent armed antibodies.
Pasche N; Neri D
Drug Discov Today; 2012 Jun; 17(11-12):583-90. PubMed ID: 22289353
[TBL] [Abstract][Full Text] [Related]
3. Antibody targeted drugs as cancer therapeutics.
Schrama D; Reisfeld RA; Becker JC
Nat Rev Drug Discov; 2006 Feb; 5(2):147-59. PubMed ID: 16424916
[TBL] [Abstract][Full Text] [Related]
4. Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation.
Frey K; Zivanovic A; Schwager K; Neri D
Integr Biol (Camb); 2011 Apr; 3(4):468-78. PubMed ID: 21225052
[TBL] [Abstract][Full Text] [Related]
5. Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6.
Hess C; Neri D
Protein Eng Des Sel; 2014 Jun; 27(6):207-13. PubMed ID: 24795343
[TBL] [Abstract][Full Text] [Related]
6. Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12.
Sommavilla R; Pasche N; Trachsel E; Giovannoni L; Roesli C; Villa A; Neri D; Kaspar M
Protein Eng Des Sel; 2010 Aug; 23(8):653-61. PubMed ID: 20551083
[TBL] [Abstract][Full Text] [Related]
7. Fibronectin extra domain B-specific aptide conjugated nanoparticles for targeted cancer imaging.
Park J; Kim S; Saw PE; Lee IH; Yu MK; Kim M; Lee K; Kim YC; Jeong YY; Jon S
J Control Release; 2012 Oct; 163(2):111-8. PubMed ID: 22964395
[TBL] [Abstract][Full Text] [Related]
8. CD70 as a therapeutic target in human malignancies.
Grewal IS
Expert Opin Ther Targets; 2008 Mar; 12(3):341-51. PubMed ID: 18269343
[TBL] [Abstract][Full Text] [Related]
9. The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases.
Rybak JN; Roesli C; Kaspar M; Villa A; Neri D
Cancer Res; 2007 Nov; 67(22):10948-57. PubMed ID: 18006840
[TBL] [Abstract][Full Text] [Related]
10. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo.
Villa A; Trachsel E; Kaspar M; Schliemann C; Sommavilla R; Rybak JN; Rösli C; Borsi L; Neri D
Int J Cancer; 2008 Jun; 122(11):2405-13. PubMed ID: 18271006
[TBL] [Abstract][Full Text] [Related]
11. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.
Junutula JR; Raab H; Clark S; Bhakta S; Leipold DD; Weir S; Chen Y; Simpson M; Tsai SP; Dennis MS; Lu Y; Meng YG; Ng C; Yang J; Lee CC; Duenas E; Gorrell J; Katta V; Kim A; McDorman K; Flagella K; Venook R; Ross S; Spencer SD; Lee Wong W; Lowman HB; Vandlen R; Sliwkowski MX; Scheller RH; Polakis P; Mallet W
Nat Biotechnol; 2008 Aug; 26(8):925-32. PubMed ID: 18641636
[TBL] [Abstract][Full Text] [Related]
12. Liposomal cytokines in the treatment of infectious diseases and cancer.
ten Hagen TL
Methods Enzymol; 2005; 391():125-45. PubMed ID: 15721378
[TBL] [Abstract][Full Text] [Related]
13. Antibody conjugates and therapeutic strategies.
McCarron PA; Olwill SA; Marouf WM; Buick RJ; Walker B; Scott CJ
Mol Interv; 2005 Dec; 5(6):368-80. PubMed ID: 16394252
[TBL] [Abstract][Full Text] [Related]
14. A human mAb specific to oncofetal fibronectin selectively targets chronic skin inflammation in vivo.
Trachsel E; Kaspar M; Bootz F; Detmar M; Neri D
J Invest Dermatol; 2007 Apr; 127(4):881-6. PubMed ID: 17185984
[TBL] [Abstract][Full Text] [Related]
15. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective.
Desjarlais JR; Lazar GA; Zhukovsky EA; Chu SY
Drug Discov Today; 2007 Nov; 12(21-22):898-910. PubMed ID: 17993407
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticle therapeutics: an emerging treatment modality for cancer.
Davis ME; Chen ZG; Shin DM
Nat Rev Drug Discov; 2008 Sep; 7(9):771-82. PubMed ID: 18758474
[TBL] [Abstract][Full Text] [Related]
17. Antibody-drug conjugates: basic concepts, examples and future perspectives.
Casi G; Neri D
J Control Release; 2012 Jul; 161(2):422-8. PubMed ID: 22306430
[TBL] [Abstract][Full Text] [Related]
18. Metabolic exploitation of the sialic acid biosynthetic pathway to generate site-specifically labeled antibodies.
Rochefort MM; Girgis MD; Ankeny JS; Tomlinson JS
Glycobiology; 2014 Jan; 24(1):62-9. PubMed ID: 24150277
[TBL] [Abstract][Full Text] [Related]
19. Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics.
MacDiarmid JA; Mugridge NB; Weiss JC; Phillips L; Burn AL; Paulin RP; Haasdyk JE; Dickson KA; Brahmbhatt VN; Pattison ST; James AC; Al Bakri G; Straw RC; Stillman B; Graham RM; Brahmbhatt H
Cancer Cell; 2007 May; 11(5):431-45. PubMed ID: 17482133
[TBL] [Abstract][Full Text] [Related]
20. Fibronectin-targeted drug delivery in cancer.
Kumra H; Reinhardt DP
Adv Drug Deliv Rev; 2016 Feb; 97():101-10. PubMed ID: 26639577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
